Please assess the completion status of the following clinical trial:

Trial Title: MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Females aged 40-62 years~* Postmenopausal or perimenopausal~* Having bothersome hot flashes~* In general good health~* Signed informed consent~Exclusion Criteria:~* Recent use of systemic hormone therapy or hormonal contraceptives~* Recent use of any prescribed, over-the-counter or herbal therapies that are taken specifically for hot flashes~* Recent use of selective estrogen receptor modulators (SERMS) or aromatase inhibitors~* Recent use of psychotropic medications, including SSRIs (selective serotonin reuptake inhibitors), serotonin-norepinephrine reuptake inhibitors (SNRIs), MAOIs (monoamine oxidase inhibitors), and other antidepressants and anxiolytics.~* Known hypersensitivity or contraindications (reasons not to take) to venlafaxine, estrogen, or progestins~* Not using a medically approved method of birth control, if sexually active and not 12 or more months since last menstrual period~* Recent drug or alcohol abuse~* Lifetime diagnosis of psychosis or bipolar disorder~* Suicide attempt in the past 3 years or any current suicidal ideation~* Current major depression (assessed during screening)~* Pregnancy, intending pregnancy, or breast feeding~* History of:~  * Pre-breast cancer or high-risk breast cancer condition~ * Abnormal bleeding suggestive of endometrial pre-cancer or endometrial hyperplasia~ * Asthma, diabetes mellitus, epilepsy, and migraine disorders that are not stable or under medical management~* Abnormal screening blood tests~* Current participation in another drug trial or intervention study~* Inability or unwillingness to complete the study procedures

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 62 Years
- Healthy Volunteers: t

Study Arms:
- Low-dose 17-ß-estradiol with progesterone taper (Type: ACTIVE_COMPARATOR): None
- Venlafaxine XR (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).